Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia

Neuropharmacology

Volumn 85, Issue , 2014, Pages 440-450

  Sciamanna, G ^a,b   Ponterio, G ^a,b   Tassone, A ^b   Maltese, M ^a   Madeo, G ^a   Martella, G ^a,b   Poli, S ^c   Schirinzi, T ^a   Bonsi, P ^b   Pisani, A ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c Addex Therapeutics SA   (Switzerland)

Author keywords

Dipraglurant; Dopamine receptor; Dystonia; Metabotropic glutamate receptor; Striatum

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; ADX 48621; CALCIUM; CELL PROTEIN; DIPRAGLURANT; DOPAMINE 2 RECEPTOR; METABOTROPIC RECEPTOR 5; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUINPIROLE; TORSIN A; UNCLASSIFIED DRUG; CHAPERONE; DYT1 PROTEIN, MOUSE; GRM5 PROTEIN, MOUSE; METABOTROPIC GLUTAMATE RECEPTOR TYPE 1; METABOTROPIC RECEPTOR; TOR1A PROTEIN, HUMAN;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; EARLY ONSET TORSION DYSTONIA; INTERNEURON; MALE; MOLECULAR IMAGING; MOUSE; NERVE CELL EXCITABILITY; NEUROMODULATION; NONHUMAN; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TORSION DYSTONIA; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; DYSTONIC DISORDERS; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; TISSUE CULTURE TECHNIQUE; TRANSGENIC MOUSE;

ANIMALS; BRAIN; CALCIUM; CHOLINERGIC NEURONS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSTONIC DISORDERS; HUMANS; INTERNEURONS; MICE, TRANSGENIC; MOLECULAR CHAPERONES; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, DOPAMINE D2; RECEPTORS, METABOTROPIC GLUTAMATE; TISSUE CULTURE TECHNIQUES;

EID: 84903539094     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.06.013     Document Type: Article

References (57)

1. L.F. Agnati, D. Guidolin, G. Albertin, E. Trivello, F. Ciruela, S. Genedani, A. Tarakanov, and K. Fuxe An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A(2A), dopamine D(2), cannabinoid CB(1), and metabotropic glutamate mGlu(5) receptors J. Recept. Signal Transduct. Res. 30 2010 355 369
2. A. Albanese, K. Bhatia, S. Bressman, M.R. Delong, S. Fahn, V.S. Fung, M. Hallett, J. Jankovic, H.A. Jinnah, C. Klein, A.E. Lang, J.W. Mink, and J.K. Teller Phenomenology and classification of dystonia: a consensus update Mov. Disord. 28 2013 863 873
3. J.M. Beaulieu, R.R. Gainetdinov, and M.G. Caron The Akt-GSK-3 signaling cascade in the actions of dopamine Trends Pharmacol. Sci. 28 2007 166 172 (Pubitemid 46483722)
4. J.M. Beaulieu, T. Del'guidice, T.D. Sotnikova, M. Lemasson, and R.R. Gainetdinov Beyond cAMP: the regulation of Akt and GSK3 by Dopamine receptors Front. Mol. Neurosci. 4 2011 38
5. M.I. Bell, P.J. Richardson, and K. Lee Functional and molecular characterization of metabotropic glutamate receptors expressed in rat striatal cholinergic interneurones J. Neurochem. 81 2002 142 149 (Pubitemid 34808861)
6. C. Blomeley, and E. Bracci Excitatory effects of serotonin on rat striatal cholinergic interneurones J. Physiol. 569 Pt 3 2005 715 721 (Pubitemid 41830217)
7. P. Bonsi, D. Cuomo, C. De Persis, D. Centonze, G. Bernardi, P. Calabresi, and A. Pisani Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons Neuropharmacology 49 Suppl. 1 2005 104 113 (Pubitemid 41115897)
8. X.O. Breakefield, A.J. Blood, Y. Li, M. Hallett, P.I. Hanson, and D.G. Standaert The pathophysiological basis of dystonias Nat. Rev. Neurosci. 9 2008 222 234 (Pubitemid 351272666)
9. N. Cabello, J. Gandía, D.C. Bertarelli, M. Watanabe, C. Lluís, R. Franco, S. Ferré, R. Luján, and F. Ciruela Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells J. Neurochem. 109 2009 1497 1507
10. M. Carbon, M. Niethammer, S. Peng, D. Raymond, V. Dhawan, T. Chaly, Y. Ma, S. Bressman, and D. Eidelberg Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia Neurology 72 2009 2097 2103
11. L.R. Castro, M. Brito, E. Guiot, M. Polito, C.W. Korn, D. Hervé, J.A. Girault, D. Paupardin-Tritsch, and P. Vincent Striatal neurones have a specific ability to respond to phasic dopamine release J. Physiol. 591 Pt 13 2013 3197 3214
12. H.T. Chen, N.Y. Ruan, J.C. Chen, and T.Y. Lin Dopamine D2 receptor-mediated Akt/PKB signalling: initiation by the D2S receptor and role in quinpirole-induced behavioural activation ASN Neuro 4 2012 371 382
13. P. DeBoer, M.J. Heeringa, and E.D. Abercrombie Spontaneous release of acetylcholine in striatum is preferentially regulated by inhibitory dopamine D2 receptors Eur. J. Pharmacol. 317 1996 257 262 (Pubitemid 27014029)
14. E. De Leonibus, F. Managò, F. Giordani, F. Petrosino, S. Lopez, A. Oliverio, M. Amalric, and A. Mele Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease Neuropsychopharmacology 34 2009 729 738
15. J.G. Doria, F.R. Silva, J.M. de Souza, L.B. Vieira, T.G. Carvalho, H.J. Reis, G.S. Pereira, T. Dobransky, and F.M. Ribeiro Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease Br. J. Pharmacol. 169 2013 909 921
16. L. Fagni, F. Ango, J. Perroy, and J. Bockaert Identification and functional roles of metabotropic glutamate receptor-interacting proteins Semin. Cell Dev. Biol. 15 2004 289 298 (Pubitemid 38581997)
17. S. Fahn High dosage anticholinergic therapy in dystonia Neurology 33 1983 1255 1261 (Pubitemid 13021184)
18. S. Ferré, M. Karcz-Kubicha, B.T. Hope, P. Popoli, J. Burgueño, M.A. Gutiérrez, V. Casadó, K. Fuxe, S.R. Goldberg, C. Lluis, R. Franco, and F. Ciruela Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function Proc. Natl. Acad. Sci. U. S. A. 99 2002 11940 11945 (Pubitemid 34994503)
19. S. Ferré, C. Quiroz, A.S. Woods, R. Cunha, P. Popoli, F. Ciruela, C. Lluis, R. Franco, K. Azdad, and S.N. Schiffmann An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors Curr. Pharm. Des. 14 2008 1468 1474 (Pubitemid 351997812)
20. T. Fuchs, R. Saunders-Pullman, I. Masuho, M.S. Luciano, D. Raymond, S. Factor, A.E. Lang, T.W. Liang, R.M. Trosch, S. White, E. Ainehsazan, D. Hervé, N. Sharma, M.E. Ehrlich, K.A. Martemyanov, S.B. Bressman, and L.J. Ozelius Mutations in GNAL cause primary torsion dystonia Nat. Genet. 45 2013 88 92
21. R.E. Goodchild, C.E. Kim, and W.T. Dauer Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope Neuron 48 2005 923 932 (Pubitemid 41814697)
22. R.E. Goodchild, K. Grundmann, and A. Pisani New genetic insights highlight 'old' ideas on motor dysfunction in dystonia Trends Neurosci. 36 2013 717 725
23. A. Granata, and T.T. Warner The role of torsinA in dystonia Eur. J. Neurol. 1 17 Suppl. 2010 81 87
24. K. Grundmann, N. Glöckle, G. Martella, G. Sciamanna, T.K. Hauser, L. Yu, S. Castaneda, B. Pichler, B. Fehrenbacher, M. Schaller, B. Nuscher, C. Haass, J. Hettich, Z. Yue, H.P. Nguyen, A. Pisani, O. Riess, and T. Ott Generation of a novel rodent model for DYT1 dystonia Neurobiol. Dis. 47 2012 61 74
25. P. Gubellini, A. Pisani, D. Centonze, G. Bernardi, and P. Calabresi Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases Prog. Neurobiol. 74 5 2004 271 300 (Pubitemid 39586720)
26. J. Jankovic Treatment of dystonia Lancet Neurol. 5 2006 864 872 (Pubitemid 44715821)
27. K.A. Johnson, and P.J. Conn Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 Modulate Akt and GSK3 β Signalling In Vivo Program No. 614.05/E26. 2013 Neuroscience Meeting Planner 2013 Society for Neuroscience San Diego, CA
28. T.H. Johnston, S.H. Fox, M.J. McIldowie, M.J. Piggott, and J.M. Brotchie Reduction of l-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease J. Pharmacol. Exp. Ther. 333 2010 865 873
29. S.P. Lee, C.H. So, A.J. Rashid, G. Varghese, R. Cheng, A.J. Lança, B.F. O'Dowd, and S.R. George Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal J. Biol. Chem. 279 2004 35671 35678 (Pubitemid 39100570)
30. C. Le Moine, and B. Bloch Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors Neuroscience 73 1996 131 143 (Pubitemid 26167662)
31. G. Levandis, E. Bazzini, M.T. Armentero, G. Nappi, and F. Blandini Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease Neurobiol. Dis. 29 2008 161 168 (Pubitemid 350180490)
32. D.M. Lovinger Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum Neuropharmacology 58 2010 951 961
33. L. Mao, L. Yang, Q. Tang, S. Samdani, G. Zhang, and J.Q. Wang The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons J. Neurosci. 25 2005 2741 2752 (Pubitemid 40365185)
34. G. Martella, M. Maltese, R. Nisticò, T. Schirinzi, G. Madeo, G. Sciamanna, G. Ponterio, A. Tassone, G. Mandolesi, V. Vanni, M. Pignatelli, P. Bonsi, and A. Pisani Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia Neurobiol. Dis. 2014 10.1016/j.nbd.2014. 01.016 [Epub ahead of print]
35. N. Morin, V.A. Jourdain, M. Morissette, L. Grégoire, and T. Di Paolo Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys Neuropharmacology 79C 2014 688 706
36. N. Morin, L. Grégoire, B. Gomez-Mancilla, F. Gasparini, and T. Di Paolo Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys Neuropharmacology 58 2010 981 986
37. F. Napolitano, M. Pasqualetti, A. Usiello, E. Santini, G. Pacini, G. Sciamanna, F. Errico, A. Tassone, V. Di Dato, G. Martella, D. Cuomo, G. Fisone, G. Bernardi, G. Mandolesi, N.B. Mercuri, D.G. Standaert, and A. Pisani Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia Neurobiol. Dis. 38 2010 434 445
38. J.S. Perlmutter, and J.W. Mink Dysfunction of dopaminergic pathways in dystonia Adv. Neurol. 94 2004 163 170
39. J.P. Pin, and R. Duvoisin The metabotropic glutamate receptors: structure and functions Neuropharmacology 34 1995 1 26
40. A. Pisani, G. Martella, A. Tscherter, P. Bonsi, N. Sharma, and G. Bernardi et al. Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia Neurobiol. Dis. 24 2006 318 325 (Pubitemid 44572750)
41. A. Pisani, G. Bernardi, J. Ding, and D.J. Surmeier Re-emergence of striatal cholinergic interneurons in movement disorders Trends Neurosci. 30 2007 545 553 (Pubitemid 47513239)
42. S. Poli Antiparkinsonian and Anti-dyskinetic Effects of Dipraglurant (ADX48621), A Novel mGluR5 Negative Allosteric Modulator in Clinical Development 2011 Presented at: the 7th International Meeting on Metabotropic Glutamate Receptors; Taormina, Sicily, Italy
43. G. Ponterio, A. Tassone, G. Sciamanna, E. Riahi, V. Vanni, P. Bonsi, and A. Pisani Powerful inhibitory action of mu opioid receptors (MOR) on cholinergic interneuron excitability in the dorsal striatum Neuropharmacology 25 2013 78 85
44. P. Popoli, A. Puzzola, M. Torvinen, R. Reggio, A. Pintor, L. Scarchilli, K. Fuxe, and S. Ferré The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors Neuropsychopharmacology 25 2001 505 513 (Pubitemid 32830955)
45. R. Rong, J.Y. Ahn, H. Huang, E. Nagata, D. Kalman, and J.A. Kapp et al. PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis Nat. Neurosci. 6 2003 1153 1161 (Pubitemid 37346035)
46. D. Rylander, H. Iderberg, Q. Li, A. Dekundy, J. Zhang, H. Li, R. Baishen, W. Danysz, E. Bezard, and M.A. Cenci A mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys Neurobiol. Dis. 39 2010 352 361
47. P. Samadi, L. Grégoire, M. Morissette, F. Calon, A. Hadj Tahar, M. Dridi, N. Belanger, L.T. Meltzer, P.J. Bédard, and T. Di Paolo mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys Neurobiol. Aging 29 2008 1040 1051 (Pubitemid 351697993)
48. G. Sciamanna, A. Tassone, G. Martella, G. Mandolesi, F. Puglisi, D. Cuomo, G. Madeo, G. Ponterio, D.G. Standaert, P. Bonsi, and A. Pisani Developmental profile of the aberrant dopamine D2 receptor response in striatal cholinergic interneurons in DYT1 dystonia PLoS One 6 2011 e24261
49. G. Sciamanna, R. Hollis, C. Ball, G. Martella, A. Tassone, A. Marshall, D. Parsons, X. Li, F. Yokoi, L. Zhang, Y. Li, A. Pisani, and D.G. Standaert Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA Neurobiol. Dis. 47 2012 416 427
50. N. Sharma, M.G. Baxter, J. Petravicz, D.C. Bragg, A. Schienda, D.G. Standaert, and X.O. Breakefield Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation J. Neurosci. 25 2005 5351 5355 (Pubitemid 40770914)
51. D.J. Sheffler, K.J. Gregory, J.M. Rook, and P.J. Conn Allosteric modulation of metabotropic glutamate receptors Adv. Pharmacol. 62 2011 37 77
52. F. Stocchi, O. Rascol, A. Destee, N. Hattori, R.A. Hauser, A.E. Lang, W. Poewe, M. Stacy, E. Tolosa, H. Gao, J. Nagel, M. Merschhemke, A. Graf, C. Kenney, and C. Trenkwalder AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study Mov. Disord. 28 2013 1838 1846
53. S.J. Tallaksen-Greene, K.W. Kaatz, C. Romano, and R.L. Albin Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons Brain Res. 780 1998 210 217 (Pubitemid 28082908)
54. F. Tison, F. Durif, J.C. Corvol, K. Eggert, C. Trenkwalder, M. Lew, S. Isaacson, C. Keywood, and O. Rascol Safety, tolerability and anti-dyskinetic efficacy of dipraglurant, a novel mGluR5 negative allosteric modulator (NAM) in Parkinson's disease (PD) patients with levodopa-induced dyskinesia (LID) Neurology 80 2013 (Meeting Abstracts 1): S23.004
55. T. Wichmann Commentary: dopaminergic dysfunction in DYT1 dystonia Exp. Neurol. 212 2 2008 242 246
56. 2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway J. Neurophysiol. 77 1997 1003 1015 (Pubitemid 27087794)
57. F.M. Zhou, C.J. Wilson, and J.A. Dani Cholinergic interneuron characteristics and nicotinic properties in the striatum J. Neurobiol. 53 2002 590 605 (Pubitemid 35375589)